Navigation Links
Viroblock SA Reports a 99% Boost of Efficacy of Facemasks Against H5N1
Date:5/5/2009

PLAN-LES-OUATES, Switzerland, May 5 /PRNewswire/ -- Viroblock SA announces that its antiviral products boosts the efficacy of facemasks by at least 99.0%, i.e. 100 times better and a peak performance of 1000 times, against avian influenza virus H5N1. Disposable facemasks are thus far not very effective against viruses, such as influenza, whose sizes are 0.02 to 0.3 microns.

Its patented technology (VCCD Tech) potentially inactivates all families and strains of enveloped viruses, like human, avian and swine Influenzas, SARS, AIDS, Ebola and smallpox viruses. VCCD Tech uses a mechanism of action that greatly limits the development of any viral resistance.

The test involved flowing air contaminated with the aerosolized avian Influenza H5N1 virus through a set of pre-impregnated facemasks. Airstreams that passed through facemasks (percolation) were then analyzed for the presence of residual infectious virus. Performance was compared to non-impregnated facemasks. This series of tests was performed at Retroscreen Virology Ltd, a recognized world leader in the research and testing of antiviral compounds and vaccines.

"We are very pleased by the excellent results obtained during the last 6 months. In-vivo campaigns (ferrets) have recently demonstrated the efficacy of VCCD Tech as an antiviral intranasal spray and this latest series of tests shows the stunning performance of our formulations on facemasks. Meanwhile the most recent ex-vivo screening campaigns prove its efficacy on additional viruses.

"H5N1 is just one of a number of emerging viruses such as SARS, and lately the swine flu, which represent a genuine threat across the globe. Viroblock has the technology platform to contribute to the development of new and innovative antiviral countermeasures, such as facemasks to protect not only frontline and government staff such as nurses, doctors, paramedics, firemen and police officers, but also the general public. I believe that Viroblock has all the assets to become a key player in pandemic influenza preparedness efforts," comments CEO Thierry Pelet.

"All these results establish the broad spectrum of action of VCDD Tech against enveloped viruses and the flexibility in its deployment. Our technology is a breakthrough for inactivating enveloped viruses and their strains; I am convinced that we have not yet exploited all its potential. I am pleased to be part of an outstanding team that works tirelessly to develop and fully exploit our technology platform," added Francois Gilardoni, member of the Board.

About Viroblock SA

Viroblock SA is a Swiss start-up founded in 2005, which has become a pioneer and world leader in the blocking virus transmission technology. Viroblock was founded by Dr. Donald F. H. Wallach who was a worldwide expert in artificial and bio-membranes, and non-phospholipid vesicles.

Its patented VCCD technology is suitable for solid supports, colloidal suspensions, emulsions, and aerosol sprays.

    Additional information is available on the company's website at
http://www.viroblock.com

    Contact:
    Dr. Thierry Pelet
    Chief Executive Officer
    Viroblock SA
    Phone: +41-22-884-8344
    E-Mail: info@viroblock.com



'/>"/>
SOURCE Viroblock SA
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
(Date:6/23/2016)... announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... ... ... Astellas is a pharmaceutical ...
Breaking Medicine Technology: